CJC-1295 With DAC vs Without DAC vs Ipamorelin

CJC-1295 with DAC, “CJC-1295 without DAC” and ipamorelin all appear in growth-hormone research, but they are not three versions of the same molecule. CJC-1295 variants are discussed as growth hormone-releasing hormone (GHRH) analogs, while ipamorelin is a growth hormone secretagogue that acts through the ghrelin receptor, also called the growth hormone secretagogue receptor (GHSR).

The practical research distinction is pathway and duration. CJC-1295 with DAC was designed for prolonged albumin binding and sustained exposure. The material commonly called CJC-1295 without DAC is short-acting and is often used online as a name for modified GRF(1-29). Ipamorelin produces a comparatively brief, episodic secretagogue signal through GHSR.

This guide compares their molecular design, receptor targets, pharmacokinetics and evidence. For the larger framework, see our guide to peptide types and the related comparison of tesamorelin vs CJC-1295 vs ipamorelin.

CJC-1295 With DAC vs Without DAC vs Ipamorelin: Quick Comparison

What Is CJC-1295 With DAC?

CJC-1295 is a synthetic analog of the first 29 amino acids of GHRH. The long-acting compound contains a reactive drug-affinity-complex group—commonly shortened to DAC—designed to bind covalently to endogenous albumin after administration. Albumin binding slows clearance and extends exposure.

In two randomized, placebo-controlled human studies, CJC-1295 produced dose-dependent increases in mean growth hormone for six days or more and IGF-1 for nine to eleven days after a single exposure. The estimated half-life was 5.8 to 8.1 days (Teichman et al., 2006).

A separate human study found that growth-hormone pulsatility was preserved one week after CJC-1295, but basal or trough GH was markedly increased. This is an important nuance: a long-acting GHRH analog does not simply create one brief pulse. It changes the hormonal background over a much longer interval (Ionescu and Frohman, 2006).

Why the DAC changes the research profile

The DAC is not a minor label difference. It is central to the compound’s pharmacokinetics. Removing the albumin-binding design changes clearance, duration and the shape of exposure. Results obtained with long-acting CJC-1295 should therefore not be transferred automatically to a short-acting GHRH analog.

Researchers comparing materials should also confirm molecular identity rather than relying on a product name alone. Our guide to peptide Certificates of Analysis explains how mass spectrometry and HPLC answer different quality questions.

What Is CJC-1295 Without DAC?

The phrase “CJC-1295 without DAC” is widely used in the peptide market, but the terminology needs care. The original clinical CJC-1295 literature concerns the long-acting albumin-binding compound. Products marketed without DAC are commonly described as modified GRF(1-29), a stabilized short fragment of GHRH.

Without the albumin-binding group, the expected research profile is shorter. The compound still belongs to the GHRH-receptor side of the comparison, but it is intended to create a more time-limited GHRH-like signal rather than the multi-day exposure documented for CJC-1295 with DAC.

Why the naming distinction matters

Calling both materials “CJC-1295” can imply that they share the same clinical evidence and half-life. They do not. A careful article, protocol or COA should specify:

• whether the DAC group is present;
• the complete or sufficiently identifying sequence;
• the expected molecular mass;
• the analytical method used for identity confirmation;
• whether a cited study evaluated the same molecular form.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue. Instead of mimicking GHRH at the GHRH receptor, it acts through a GHRP-like receptor now understood as the ghrelin receptor or GHSR.

In a human pharmacokinetic-pharmacodynamic study, ipamorelin had a short terminal half-life of approximately two hours and produced a single episode of GH release, with a peak at roughly 0.67 hours followed by decline toward negligible concentrations (Gobbert et al., 1999).

Early pharmacological profiling described ipamorelin as selective for GH release compared with older GHRPs. Much of that selectivity work was performed in animals, including the finding that ipamorelin did not significantly raise ACTH or cortisol in the studied swine model (Raun et al., 1998). That preclinical result should not be overstated as a universal human safety conclusion.

GHRH Receptor vs Ghrelin Receptor

How CJC-1295 signals

CJC-1295 variants act as GHRH analogs. They engage GHRH receptors on pituitary somatotroph cells and support the signaling pathway normally activated by hypothalamic GHRH.

How ipamorelin signals

Ipamorelin acts through GHSR, a separate receptor system associated with ghrelin and synthetic GH secretagogues. The pathway can stimulate GH release through mechanisms that are complementary to GHRH signaling, but “complementary” does not prove that every combination produces a superior outcome.

Why two pathways are studied together

Research interest in GHRH analog–secretagogue combinations comes from engaging two inputs into GH release. However, there is limited direct human trial evidence for the specific combinations commonly discussed online. Mechanistic logic should be identified as a hypothesis rather than presented as established clinical superiority.

DAC vs No DAC: The Main Pharmacokinetic Difference

The simplest way to understand DAC is as a duration modifier:

• with DAC: albumin association produces prolonged exposure measured in days;
• without DAC: no albumin-binding extension, so the GHRH-like signal is shorter;
• ipamorelin: a separate GHSR agonist with a short human half-life and episodic GH response.

Longer is not automatically better. A sustained research signal and a short pulse answer different experimental questions. Study design should follow the biological hypothesis, sampling schedule and validated model.

Which Compound Has the Strongest Human Evidence?

The evidence bases are not equivalent:

• CJC-1295 with DAC has controlled human pharmacology studies documenting prolonged GH and IGF-1 changes.
• CJC-1295 without DAC has a large online research profile but substantially less direct human evidence under that exact name and molecular definition.
• Ipamorelin has human PK/PD data describing short exposure and episodic GH release, while many selectivity claims originate in animal work.

This does not rank them as products. It ranks the kinds of conclusions that the published evidence can support.

Quality Questions for CJC-1295 and Ipamorelin Research

Before comparing results, confirm:

1. the exact compound and molecular form;
2. whether CJC-1295 contains DAC;
3. identity by an appropriate mass-based method;
4. chromatographic purity;
5. measured vial content where quantity matters;
6. batch-specific documentation;
7. storage and handling history.

See our peptide storage and stability guide for the factors that can affect material after release testing.

Explore CJC-1295 and Ipamorelin

Great Northern Peptides offers research products including CJC-1295 with DAC, the CJC-1295 no DAC / ipamorelin blend and ipamorelin. Review the exact product identity and batch documentation rather than selecting by abbreviation alone.

Frequently Asked Questions